The tool was created based on the analysis of data from 961 patients, 651 of whom had mild dementia and 310 had mild cognitive impairment. All patients had amyloid plaques in their brains, which are characteristic of Alzheimer’s disease.
A research team led by Pieter van der Veer from the University of Amsterdam analyzed MRI scans, biomarkers in cerebrospinal fluid, patients’ age, gender and medical history.
The main evaluation criterion was the number of scores on cognitive tests: from 26.4 in patients with mild cognitive impairment to 22.4 in patients with mild dementia.
The results showed that patients with mild cognitive impairment lost an average of 5.4 points over 5 years, while patients with mild dementia lost 14.6 points. The test also showed that medications can slow this process and prolong the time until moderate dementia is achieved.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
